Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis
Trial Parameters
Brief Summary
A Phase 2 study designed to evaluate the efficacy and safety of CM512 in adult patients with moderate-to-severe Atopic Dermatitis (AD).
Eligibility Criteria
Inclusion Criteria: * Patients with a diagnosis of AD for at least 1 year according to the American Academy of Dermatology's consensus criteria prior to the screening visit meeting all of the following criteria: * EASI≥16 at Screening and Baseline visits; * Investigator's Global Assessment (IGA) score of≥3 at Screening and Baseline visits; * 10% Body Surface Area (BSA) of AD involvement at Screening and Baseline visits; * Mean of weekly Pruritus Numeric Rating Scale (NRS) severity score≥4 at Baseline; Exclusion Criteria: * Not enough washing-out period for previous therapy. * Concurrent disease/status which may potentially affect the efficacy/safety judgement. * Organ dysfunction. * Pregnancy. * Other.